PL BioScience GmbH
PL BioScience GmbH is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at PL BioScience GmbH.
PL BioScience GmbH is a company.
Key people at PL BioScience GmbH.
PL BioScience GmbH is a life science company based in Aachen, Germany, specializing in the production and development of Human Platelet Lysate (HPL), an animal-free cell culture supplement that supports cell expansion for research, regenerative medicine, and GMP-compliant cell therapies.[1][2][5] Its flagship ELAREM™ product line offers a complete portfolio from standard lab use to clinical applications, replacing traditional Fetal Bovine Serum (FBS) with a consistent, ethically sourced alternative rich in growth factors that enhances cell proliferation, viability, and physiological relevance.[4][7] The company serves academic researchers, biotech firms, and cell/gene therapy developers, solving key challenges like batch variability, contamination risks, and ethical concerns in cell culture, while demonstrating strong growth through investments, production scaling, and innovation in artificial HPL (aHPL).[2][3]
Founded in 2015 within the ecosystem of RWTH Aachen University, PL BioScience emerged from an academic environment with the vision to provide safe, animal-component-free cell culture tools derived from human platelets.[5][6] The company secured the EXIST Business Start-up Grant from the German Federal Ministry for Economic Affairs and Energy in its first year, fueling early development, and later joined the Scale-up.NRW program (Batch #4).[5] This academic spinout quickly translated research into commercial products, starting with donor-derived HPL and evolving to address scalability limits in regenerative medicine, marking pivotal moments like the 2025 launch of the world's first artificial HPL in partnership with DewCell Biotherapeutics.[3][4]
PL BioScience rides the explosive growth of cell and gene therapies in oncology, regenerative medicine, and stem cell applications, where demand for reliable, animal-free culture media is surging amid regulatory pushes for ethical, consistent alternatives to FBS.[2][3] Timing is ideal as clinical approvals accelerate and commercialization scales, but donor-dependent supplies risk bottlenecks—PL BioScience counters this as Europe's only EU-sourced HPL provider and pioneer of aHPL, ensuring supply chain resilience.[3][4] Market forces like sustainability mandates and contamination risks favor its standardized, physiologically relevant products, influencing the ecosystem by enabling faster translation from lab to patient therapies and supporting biopharma's shift to advanced manufacturing.[1][2]
PL BioScience is poised to dominate HPL as the gold standard for cell culture, with its Aachen expansion and aHPL patent solidifying scalability for global demand in next-gen therapies.[3][4] Trends like AI-driven drug discovery, personalized medicine, and Asia-Pacific growth will amplify its trajectory, potentially through further partnerships and biopharma acquisitions.[3] Its influence may evolve from niche innovator to essential upstream enabler, much like how specialized reagents transformed biotech—bridging today's research needs with tomorrow's commercial therapies, as it began with a university grant to redefine ethical cell expansion.[5]
Key people at PL BioScience GmbH.
